Effects of the Discontinuation of Antihypertensive Treatment on Neuropsychiatric Symptoms and Quality of Life in Nursing Home Residents with Dementia (DANTON): a Multicentre, Open-label, Blinded-outcome, Randomised Controlled Trial

Overview

Journal Age Ageing

Publisher Oxford University Press

Specialty Geriatrics

Date 2024 Jul 6

PMID 38970547

Authors

Jonathan M K Bogaerts

Jacobijn Gussekloo

Bianca E M de Jong-Schmit

Saskia le Cessie

Simon P Mooijaart

Roos C van der Mast

Wilco P Achterberg

Rosalinde K E Poortvliet

Affiliations

Soon will be listed here.

Abstract

Background: Based on observational studies and randomised controlled trials (RCTs), the benefit-harm balance of antihypertensive treatment in older adults with dementia is unclear.

Objective: To assess whether discontinuing antihypertensive treatment reduces neuropsychiatric symptoms (NPSs) and maintains quality of life (QoL) in nursing home residents with dementia.

Design: Open-label, blinded-outcome RCT. Randomisation 1:1, stratified by nursing home organisation and baseline NPS. Trial registration: NL7365.

Subjects: Dutch long-term care residents with moderate-to-severe dementia and systolic blood pressure (SBP) ≤160 mmHg during antihypertensive treatment. Exclusion criteria included heart failure NYHA-class-III/IV, recent cardiovascular events/procedures or life expectancy <4 months (planned sample size n = 492).

Measurements: Co-primary outcomes NPS (Neuropsychiatric Inventory-Nursing Home [NPI-NH]) and QoL (Qualidem) at 16 weeks.

Results: From 9 November 2018 to 4 May 2021, 205 participants (median age 85.8 [IQR 79.6-89.5] years; 79.5% female; median SBP 134 [IQR 123-146] mmHg) were randomised to either antihypertensive treatment discontinuation (n = 101) or usual care (n = 104). Safety concerns, combined with lacking benefits, prompted the data safety and monitoring board to advice a premature cessation of randomisation. At 16-week follow-up, no significant differences were found between groups for NPI-NH (adjusted mean difference 1.6 [95% CI -2.3 to 5.6]; P = 0.42) or Qualidem (adjusted mean difference - 2.5 [95% CI -6.0 to 1.0]; P = 0.15). Serious adverse events (SAEs) occurred in 36% (discontinuation) and 24% (usual care) of the participants (adjusted hazard ratio 1.65 [95% CI 0.98-2.79]). All 32-week outcomes favoured usual care.

Conclusion: Halfway through this study, a non-significant increased SAE risk associated with discontinuing antihypertensive treatment was observed, and an associated interim analysis showed that significant worthwhile health gain for discontinuation of antihypertensive treatment was unlikely. This unbeneficial benefit-harm balance shows that discontinuation of antihypertensive treatment in this context does not appear to be either safe or beneficial enough to be recommended in older adults with dementia.

Citing Articles

Challenging the status quo: deprescribing antihypertensive medication in older adults in primary care.

Sheppard J, McManus R Br J Gen Pract. 2024; 74(748):484-486.

PMID: 39481908 PMC: 11526736. DOI: 10.3399/bjgp24X739689.

References

Daamen M, Hamers J, Gorgels A, Brunner-La Rocca H, Tan F, van Dieijen-Visser M . Heart failure in nursing home residents; a cross-sectional study to determine the prevalence and clinical characteristics. BMC Geriatr. 2015; 15:167. PMC: 4681153. DOI: 10.1186/s12877-015-0166-1. View

Moonen J, Foster-Dingley J, de Ruijter W, van der Grond J, Bertens A, van Buchem M . Effect of Discontinuation of Antihypertensive Treatment in Elderly People on Cognitive Functioning--the DANTE Study Leiden: A Randomized Clinical Trial. JAMA Intern Med. 2015; 175(10):1622-30. DOI: 10.1001/jamainternmed.2015.4103. View

Etherton-Beer C, Page A, Naganathan V, Potter K, Comans T, Hilmer S . Deprescribing to optimise health outcomes for frail older people: a double-blind placebo-controlled randomised controlled trial-outcomes of the Opti-med study. Age Ageing. 2023; 52(5). PMC: 10226731. DOI: 10.1093/ageing/afad081. View

Harrison J, der Wardt V, Conroy S, Stott D, Dening T, Gordon A . New horizons: the management of hypertension in people with dementia. Age Ageing. 2016; 45(6):740-746. PMC: 5863782. DOI: 10.1093/ageing/afw155. View

Sheppard J, Burt J, Lown M, Temple E, Lowe R, Fraser R . Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial. JAMA. 2020; 323(20):2039-2051. PMC: 7251449. DOI: 10.1001/jama.2020.4871. View

Benetos A, Petrovic M, Strandberg T . Hypertension Management in Older and Frail Older Patients. Circ Res. 2019; 124(7):1045-1060. DOI: 10.1161/CIRCRESAHA.118.313236. View

Reisberg B, Ferris S, de Leon M, Crook T . The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982; 139(9):1136-9. DOI: 10.1176/ajp.139.9.1136. View

Cummings J . The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997; 48(5 Suppl 6):S10-6. DOI: 10.1212/wnl.48.5_suppl_6.10s. View

Hurley A, Volicer B, Hanrahan P, Houde S, Volicer L . Assessment of discomfort in advanced Alzheimer patients. Res Nurs Health. 1992; 15(5):369-77. DOI: 10.1002/nur.4770150506. View

10.

Inouye S, van Dyck C, Alessi C, Balkin S, Siegal A, Horwitz R . Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990; 113(12):941-8. DOI: 10.7326/0003-4819-113-12-941. View

11.

Welsh T, Gordon A, Gladman J . Treatment of Hypertension in People With Dementia: A Multicenter Prospective Observational Cohort Study. J Am Med Dir Assoc. 2019; 20(9):1111-1115. DOI: 10.1016/j.jamda.2019.03.036. View

12.

Streit S, Poortvliet R, Gussekloo J . Lower blood pressure during antihypertensive treatment is associated with higher all-cause mortality and accelerated cognitive decline in the oldest-old. Data from the Leiden 85-plus Study. Age Ageing. 2018; 47(4):545-550. DOI: 10.1093/ageing/afy072. View

13.

Brouwer W, van Exel N, van Gorp B, Redekop W . The CarerQol instrument: a new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. Qual Life Res. 2006; 15(6):1005-21. DOI: 10.1007/s11136-005-5994-6. View

14.

Lueken U, Seidl U, Volker L, Schweiger E, Kruse A, Schroder J . Development of a short version of the Apathy Evaluation Scale specifically adapted for demented nursing home residents. Am J Geriatr Psychiatry. 2007; 15(5):376-85. DOI: 10.1097/JGP.0b013e3180437db3. View

15.

Hoefman R, van Exel J, Rose J, van de Wetering E, Brouwer W . A discrete choice experiment to obtain a tariff for valuing informal care situations measured with the CarerQol instrument. Med Decis Making. 2013; 34(1):84-96. DOI: 10.1177/0272989X13492013. View

16.

Reeve E, Jordan V, Thompson W, Sawan M, Todd A, Gammie T . Withdrawal of antihypertensive drugs in older people. Cochrane Database Syst Rev. 2020; 6:CD012572. PMC: 7387859. DOI: 10.1002/14651858.CD012572.pub2. View

17.

Tariot P, Cummings J, Katz I, Mintzer J, Perdomo C, Schwam E . A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2002; 49(12):1590-9. View

18.

Wood S, Cummings J, Hsu M, Barclay T, Wheatley M, Yarema K . The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry. 2000; 8(1):75-83. DOI: 10.1097/00019442-200002000-00010. View

19.

Katz S, Ford A, Moskowitz R, Jackson B, JAFFE M . STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. JAMA. 1963; 185:914-9. DOI: 10.1001/jama.1963.03060120024016. View

20.

Klapwijk M, Caljouw M, Pieper M, van der Steen J, Achterberg W . Characteristics Associated with Quality of Life in Long-Term Care Residents with Dementia: A Cross-Sectional Study. Dement Geriatr Cogn Disord. 2016; 42(3-4):186-197. PMC: 5290445. DOI: 10.1159/000448806. View